- $489.43m
- $601.01m
- $297.18m
Evolus Q2 revenue rises 21%, lifts 2026 outlook
Brief: Evolus Q2 Product Revenue USD 83.35 Million
Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe
Evolus Q1 revenue rises 7% on product sales
Preview: Weight-loss revolution sparks new appetite for aesthetics firms
U.S. STOCKS ON THE MOVE-AnaptysBio, Tesla, Intel
Evolus soars after Q4 revenue jump
Brief: Evolus Inc - Enters Loan And Security Agreement With Eclipse Business Capital On March 3, 2026 - SEC Filing
Evolus Q4 revenue rises
U.S. RESEARCH ROUNDUP- Cencora, Crocs, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Green Brick Partners, Pultegroup, Toll Brothers
Brief: Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evolus Q3 revenue rises, reaffirms 2025 revenue forecast
Brief: Evolus Q3 Product Revenue USD 68.967 Million
Brief: Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Evolus Announces The Appointment Of Tatjana Mitchell As Chief Financial Officer
Brief: Evolus Announces Positive Results For Evolysse Sculpt Study
Evolus Inc reports results for the quarter ended June 30 - Earnings Summary